300 related articles for article (PubMed ID: 2509910)
21. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group.
Kieburtz K; McDermott M; Como P; Growdon J; Brady J; Carter J; Huber S; Kanigan B; Landow E; Rudolph A
Neurology; 1994 Sep; 44(9):1756-9. PubMed ID: 7936311
[TBL] [Abstract][Full Text] [Related]
22. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group.
McDermott MP; Jankovic J; Carter J; Fahn S; Gauthier S; Goetz CG; Golbe LI; Koller W; Lang AE; Olanow CW
Arch Neurol; 1995 Jun; 52(6):565-70. PubMed ID: 7763203
[TBL] [Abstract][Full Text] [Related]
23. Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.
Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
Arch Neurol; 1989 Dec; 46(12):1280-3. PubMed ID: 2511825
[TBL] [Abstract][Full Text] [Related]
24. The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor.
Przuntek H; Kuhn W
J Neural Transm Suppl; 1987; 25():97-104. PubMed ID: 3123607
[TBL] [Abstract][Full Text] [Related]
25. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
Presthus J; Berstad J; Lien K
Acta Neurol Scand; 1987 Sep; 76(3):200-3. PubMed ID: 3120487
[TBL] [Abstract][Full Text] [Related]
26. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
Shoulson I
Ann Neurol; 1998 Sep; 44(3 Suppl 1):S160-6. PubMed ID: 9749589
[TBL] [Abstract][Full Text] [Related]
27. Deprenyl (selegiline) in the treatment of Parkinson's disease.
Birkmayer W
Acta Neurol Scand Suppl; 1983; 95():103-5. PubMed ID: 6428140
[TBL] [Abstract][Full Text] [Related]
28. (-)Deprenyl in Parkinson's disease: a two-year study in the different evolutive stages.
Giovannini P; Martignoni E; Piccolo I; Pacchetti C; Grassi MP; Nappi G; Caraceni T
J Neural Transm Suppl; 1986; 22():235-46. PubMed ID: 3097258
[TBL] [Abstract][Full Text] [Related]
29. Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
Birkmayer W; Birkmayer GD
J Neural Transm Suppl; 1986; 22():219-25. PubMed ID: 3097256
[TBL] [Abstract][Full Text] [Related]
30. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.
Golbe LI; Lieberman AN; Muenter MD; Ahlskog JE; Gopinathan G; Neophytides AN; Foo SH; Duvoisin RC
Clin Neuropharmacol; 1988 Feb; 11(1):45-55. PubMed ID: 3127050
[TBL] [Abstract][Full Text] [Related]
31. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
[TBL] [Abstract][Full Text] [Related]
32. R-(-)-deprenyl in the treatment of end-of-dose akinesia.
Ulm G; Fornadi F
J Neural Transm Suppl; 1987; 25():163-72. PubMed ID: 3123603
[TBL] [Abstract][Full Text] [Related]
33. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.
Schachter M; Marsden CD; Parkes JD; Jenner P; Testa B
J Neurol Neurosurg Psychiatry; 1980 Nov; 43(11):1016-21. PubMed ID: 6777463
[TBL] [Abstract][Full Text] [Related]
34. Selegiline in the treatment of Parkinson's disease--long term experience.
Yahr MD; Elizan TS; Moros D
Acta Neurol Scand Suppl; 1989; 126():157-61. PubMed ID: 2515721
[TBL] [Abstract][Full Text] [Related]
35. Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment.
LeWitt PA
J Neural Transm Suppl; 1994; 43():171-81. PubMed ID: 7884399
[TBL] [Abstract][Full Text] [Related]
36. Deprenyl and the progression of Parkinson's disease.
Science; 1990 Jul; 249(4966):303-4. PubMed ID: 2115691
[No Abstract] [Full Text] [Related]
37. (-)Deprenyl in the treatment of decompensated Parkinson's disease.
Csanda E; Tárczy M; Takáts A
J Neural Transm Suppl; 1986; 22():247-52. PubMed ID: 3097259
[TBL] [Abstract][Full Text] [Related]
38. Deprenyl in Parkinson's disease.
Lancet; 1982 Sep; 2(8300):695-6. PubMed ID: 6126632
[No Abstract] [Full Text] [Related]
39. R-(-)-deprenyl and parkinsonism.
Yahr MD
J Neural Transm Suppl; 1987; 25():5-12. PubMed ID: 3123605
[TBL] [Abstract][Full Text] [Related]
40. New approaches in the use of selegiline for the treatment of Parkinson's disease.
Lees AJ; Frankel J; Eatough V; Stern GM
Acta Neurol Scand Suppl; 1989; 126():139-45. PubMed ID: 2515719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
